Abstract
Rectum and lung normal tissue complication probability: a retrospective analysis depending on different numbers of fractions and different dose-limits
Highlights
Prostate cancer is one of the predominant malignancies in men through the world as well as non-small cell lung cancer (NSCLC) it continues to be the leading cause of cancer-related mortality
Due to the high interest in hypofractionated treatments [9], the goal of this study is to investigate the normal tissue complication probability (NTCP) variation when the number of fractions is changed and the dose per fraction is adjusted to maintaining rectum and lung dose-limits constraints (VD) as per original standard (2 Gy/day) dose plan
The 3-dimensional conformal radiotherapy treatment (3DCRT) versus intensity-modulated radiation treatment (IMRT) prostate group comparison did not point out statistically significant differences
Summary
Prostate cancer is one of the predominant malignancies in men through the world as well as non-small cell lung cancer (NSCLC) it continues to be the leading cause of cancer-related mortality. External beam irradiation regimes have been used delivering 2 Gy given in 5 days per week over 7.6 weeks for prostate treatments and 2 Gy daily for a total dose of 60-66 Gy over 6 weeks or more for lung, an increasing number of radiotherapy departments have implemented in the recent years hypofractionated regimens for both malignancies sites. While standard radiation dose is given over a period of 7-9 weeks, hypofractionation is defined as dose per fraction in the range of 2.2 Gy up to 4.0 Gy or extreme hypofractionation with a single dose beyond 4.0 Gy allowing treatments over a shorter time span. Even though studies have shown hypofractionation can be safe and effective it is still entirely unclear regarding the effect of a large dose per fraction on normal tissues and organs at risk surrounding tumor volume. Adverse events seem to be dependent upon both the total radiation dose and the volume of the rectum and lung included in the high dose region
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
